Table 1.
Characteristics of melanoma patients and tumor samples.
| Type of Therapy at the Time of Blood Sampling | |||||
|---|---|---|---|---|---|
| Number of Patients (%) | Metastases Peresent (%) | None (%) |
Immuno-Therapy a (%) |
Targeted Therapy b (%) | |
| All patients | 151 (100) | 68 (45.0) | 64 (43.4) | 64 (43.4) | 23 (15.2) |
| Gender | |||||
| Female | 67 (44.4) | 23 (34.3) | 31 (46.2) | 27 (40.3) | 9 (13.4) |
| Male | 84 (55.6) | 45 (53.6) | 33 (33.3) | 37 (44.0) | 14 (16.7) |
| Age (years) (average age: 61.91) | |||||
| 20–50 | 28 (18.5) | 8 (28.6) | 14 (50.0) | 9 (32.1) | 5 (17.9) |
| ≥50 | 123 (81.5) | 60 (48.8) | 50 (40.7) | 55(44.7) | 18 (14.6) |
| Metastasis | |||||
| Absent | 83 (55.0) | 83 (55.0) | 53 (63.9) | 22 (26.5) | 8 (9.6) |
| Present | 68 (45.0) | 68 (45.0) | 11 (16.2) | 42 (61.8) | 15 (22.1) |
| Pathway of metastasis | |||||
| Lymphatic (only lymph node) | 19 (12.6) | ||||
| Hematogenous (distant and/or cutan) | 49 (32.5) | ||||
| Patient’s survival (with a 3-year follow-up period) | |||||
| Alive | 129 (85.4) | ||||
| Deceased | 22 (14.6) | ||||
a Immunotherapies: OPDIVO® (nivolumab); OPDIVO® (nivolumab) + YERVOY® (ipilimumab); Keytruda (pembrolizumab). b Targeted therapies: TAFINLAR® (dabrafenib)+MEKINIST® (trametinib); Zelboraf (vemurafenib) + COTELLIC® (cobimetinib).